Roche Sees Global Regulatory "Tightening," Not FDA "Slowdown"
Executive Summary
The recent signs of tougher product reviews by global regulators reflect the need for better post-marketing surveillance in light of accelerated pharmaceutical development timelines, Roche suggested during an Aug. 16 media briefing in New York City.
You may also be interested in...
Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication
Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.
Accutane Psychiatric Safety Trial Planned: Roche Prepares For Hearings
Roche and FDA are in discussions about the design for a prospective study to resolve questions about a potential link between the acne drug Accutane (isotretinoin) and psychiatric side effects.
Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication
Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.